Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $1.5 million.

  • Fennec Pharmaceuticals' Cash from Operations rose 16767.91% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 13384.34%. This contributed to the annual value of $27.0 million for FY2024, which is 25738.2% up from last year.
  • Fennec Pharmaceuticals' Cash from Operations amounted to $1.5 million in Q3 2025, which was up 16767.91% from -$3.7 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Cash from Operations ranged from a high of $39.0 million in Q1 2024 and a low of -$8.4 million during Q2 2024
  • In the last 5 years, Fennec Pharmaceuticals' Cash from Operations had a median value of -$3.6 million in 2021 and averaged -$1.2 million.
  • The largest annual percentage gain for Fennec Pharmaceuticals' Cash from Operations in the last 5 years was 80014.34% (2024), contrasted with its biggest fall of 11254.43% (2024).
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Cash from Operations stood at -$3.0 million in 2021, then crashed by 129.95% to -$6.8 million in 2022, then grew by 28.55% to -$4.9 million in 2023, then soared by 69.67% to -$1.5 million in 2024, then skyrocketed by 201.29% to $1.5 million in 2025.
  • Its Cash from Operations stands at $1.5 million for Q3 2025, versus -$3.7 million for Q2 2025 and -$4.3 million for Q1 2025.